Patents by Inventor Dario Lehoux

Dario Lehoux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ORITAVANCIN FORMULATIONS
    Publication number: 20170239323
    Abstract: Disclosed herein are antibacterial compositions, pharmaceutical compositions, and the use and preparation thereof. Some embodiments relate to compositions including oritavancin and their use as therapeutic agents.
    Type: Application
    Filed: February 17, 2017
    Publication date: August 24, 2017
    Inventors: David C. Griffith, Adel Rafai Far, Dario Lehoux, Gopal Krishna
  • Methods of treating bacterial infections using oritavancin
    Patent number: 9682061
    Abstract: The present invention is directed to methods of treating a bacterial infection in a subject through the administration of a therapeutically effective amount of a glycopeptide antibiotic to a subject having a bacterial infection. The effective amount of the glycopeptide antibiotic that is administered to the subject provides a fraction of the glycopeptide antibiotic administered to the subject bound to serum proteins within the subject and within a selected range.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: June 20, 2017
    Assignee: THE MEDICINES COMPANY
    Inventors: Dario Lehoux, Thomas Parr, Jr., Gregory Moeck
  • Method of inhibiting by administration of oritavancin
    Patent number: 9220749
    Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of C. difficile and C. difficile spores. Methods for the treatment, prophylaxis and prevention of C. difficile infection and disease in animals, including humans, are described.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: December 29, 2015
    Assignee: THE MEDICINES COMPANY
    Inventors: Mark Harvey Wilcox, Simon Baines, Dario Lehoux, Thomas R. Parr
  • METHOD OF INHIBITING CLOSTRIDIUM DIFFICILE BY ADMINISTRATION OF ORITAVANCIN
    Publication number: 20140100157
    Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of C. difficile and C. difficile spores. Methods for the treatment, prophylaxis and prevention of C. difficile infection and disease in animals, including humans, are described.
    Type: Application
    Filed: December 10, 2013
    Publication date: April 10, 2014
    Applicant: THE MEDICINES COMPANY
    Inventors: Mark Harvey WILCOX, Simon BAINES, Dario LEHOUX, Thomas R. PARR
  • Method of inhibiting clostridium difficile by administration of oritavancin
    Patent number: 8629100
    Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of C. difficile and C. difficile spores. Methods for the treatment, prophylaxis and prevention of C. difficile infection and disease in animals, including humans, are described.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: January 14, 2014
    Assignee: The Medicines Company
    Inventors: Mark Harvey Wilcox, Simon Baines, Dario Lehoux, Thomas R. Parr
  • METHOD OF INHIBITING CLOSTRIDIUM DIFFICILE BY ADMINISTRATION OF ORITAVANCIN
    Publication number: 20130310308
    Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of C. difficile and C. difficile spores. Methods for the treatment, prophylaxis and prevention of C. difficile infection and disease in animals, including humans, are described.
    Type: Application
    Filed: July 24, 2013
    Publication date: November 21, 2013
    Applicant: The Medicines Company
    Inventors: Mark Harvey WILCOX, Simon BAINES, Dario LEHOUX, Thomas R. PARR
  • Method of inhibiting clostridium difficile by administration of oritavancin
    Patent number: 8518873
    Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of C. difficile and C. difficile spores. Methods for the treatment, prophylaxis and prevention of C. difficile infection and disease in animals, including humans, are described.
    Type: Grant
    Filed: September 11, 2008
    Date of Patent: August 27, 2013
    Assignee: The Medicines Company
    Inventors: Mark Harvey Wilcox, Simon Baines, Dario Lehoux, Thomas R. Parr
  • Methods of treatment using single doses of oritavancin
    Patent number: 8420592
    Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described.
    Type: Grant
    Filed: August 29, 2009
    Date of Patent: April 16, 2013
    Assignee: The Medicines Company
    Inventors: Dario Lehoux, Thomas R. Parr, Gregory Moeck, Pierre Etienne
  • METHODS OF TREATING BACTERIAL INFECTIONS USING ORITAVANCIN
    Publication number: 20120035097
    Abstract: The present invention is directed to methods of treating a bacterial infection in a subject through the administration of a therapeutically effective amount of a glycopeptide antibiotic to a subject having a bacterial infection. The effective amount of the glycopeptide antibiotic that is administered to the subject provides a fraction of the glycopeptide antibiotic administered to the subject bound to serum proteins within the subject and within a selected range.
    Type: Application
    Filed: April 26, 2010
    Publication date: February 9, 2012
    Applicant: TARGANTA THERAPEUTICS CORP.
    Inventors: Geoffrey Andrew McKay, Sylvain Beaulieu, Dario Lehoux, Thomas Parr, JR., Gregory Moeck
  • METHODS OF TREATMENT USING SINGLE DOSES OF ORITAVANCIN
    Publication number: 20110201546
    Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described.
    Type: Application
    Filed: August 29, 2009
    Publication date: August 18, 2011
    Applicant: TARGANTA THERAPEUTICS CORP.
    Inventors: Dario Lehoux, Thomas R Parr, Gregory Moeck, Pierre Etienne
  • METHOD OF INHIBITING CLOSTRIDIUM DIFFICILE BY ADMINISTRATION OF ORITAVANCIN
    Publication number: 20100311646
    Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of C. difficile and C. difficile spores. Methods for the treatment, prophylaxis and prevention of C. difficile infection and disease in animals, including humans, are described.
    Type: Application
    Filed: September 11, 2008
    Publication date: December 9, 2010
    Applicant: TARGANTA THERAPEUTICS CORP.
    Inventors: Mark Harvey Wilcox, Simon Baines, Dario Lehoux, Thomas R. Parr